Compare Ferrari NV (RACE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Recursion Pharmaceuticals Inc — how do they compare? Ferrari NV trades at $389.63 (market cap $67.35B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Ferrari NV is far larger — about 31.5× Recursion Pharmaceuticals Inc's market cap, and Ferrari NV pays a 1.09% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RACE | RXRX | |
|---|---|---|
Market Cap | $67.35B | $2.14B |
Volume | 390,618 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $6.79 |
52-Week Low | $314.63 | $2.84 |
Typical Hold Time | 126 Days | 22 Days |
Enterprise Value | $69.22B | $1.66B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $386.39, down slightly by 0.03% today. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $2.49 vs. $2.44 expected, Q1 2026: $2.73 vs. $2.70 expected, Q2 2026: $2.99 vs. $2.83 expected) and robust profitability (net margin 22.25%, ROE 45.45%). Technical indicators are bearish overall, with the current price near support at $385. Recent news highlights a share buyback program and partnership with Rakuten effective January 2027.
Outlook: Analyst consensus is bullish with a $462.75 price target (73.69% buy ratings). Opportunities include strong brand equity, margin expansion, and strategic initiatives. Risks involve high valuation multiples (P/E 37.19, P/S 8.25), economic sensitivity, and execution of growth plans. The stock offers growth potential but requires monitoring of valuation and market conditions.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
